Anbio Biotechnology (FRA:N3B) Other Current Payables: €0.08 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:N3B Anbio Biotechnology FRA:N3B
24 GF Score
Price €8.05
! 2 Warning Signs
View Full Analysis

What is Anbio Biotechnology Other Current Payables?

Anbio Biotechnology FRA:N3B +4.55% 24 Other Current Payables is €0.08 Mil as of Dec. 2025. GuruFocus rates FRA:N3B with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

Anbio Biotechnology's Other Current Payables for the quarter that ended in Dec. 2025 was €0.08 Mil.

Anbio Biotechnology's quarterly Other Current Payables declined from Dec. 2024 (€0.10 Mil) to Jun. 2025 (€0.00 Mil) but then increased from Jun. 2025 (€0.00 Mil) to Dec. 2025 (€0.08 Mil).

Anbio Biotechnology's annual Other Current Payables declined from Dec. 2023 (€0.15 Mil) to Dec. 2024 (€0.10 Mil) and declined from Dec. 2024 (€0.10 Mil) to Dec. 2025 (€0.08 Mil).

Anbio Biotechnology Other Current Payables Related Terms

Anbio Biotechnology Other Current Payables Historical Data

* Premium members only.

The historical data trend for Anbio Biotechnology's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anbio Biotechnology Other Current Payables Chart

Anbio Biotechnology Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
0.00 0.00 0.15 0.10 0.08

Anbio Biotechnology Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only 0.15 0.05 0.10 0.00 0.08
FRA:N3B
24GF Score
Anbio Biotechnology FRA:N3B
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anbio Biotechnology Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €0.08 Mil mean?
Anbio Biotechnology (FRA:N3B) has a Other Current Payables of €0.08 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Anbio Biotechnology and its competitors.
Is Anbio Biotechnology's Other Current Payables too high?
Anbio Biotechnology's current Other Current Payables is €0.08 Mil. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's Other Current Payables compare to ANGO and OSUR?
Anbio Biotechnology's Other Current Payables of €0.08 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Medical Devices & Instruments company?
A good Other Current Payables depends on the Medical Devices & Instruments industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Anbio Biotechnology and its competitors. Anbio Biotechnology's current Other Current Payables is €0.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (FRA:N3B) has a current Other Current Payables of €0.08 Mil. The current Other Current Payables is €0.08 Mil. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Anbio Biotechnology (FRA:N3B), the current Other Current Payables is €0.08 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anbio Biotechnology Business Description

Other Exchanges NNNN:USA
Address Friedrich-Ebert-Anlage 35-37, Frankfurt am Main, HE, DEU, 60327
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score

Get the complete analysis for FRA:N3B

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.05
Price